Sartorius, a leading international partner of life science research and the biopharmaceutical industry, successfully placed a note loan with a volume of 750 million euros. The note loan was issued with maturity terms of 3, 5, 7 and 10 years and was significantly oversubscribed. “We see such great interest as clear proof of our attractiveness for investors,” said Rainer Lehmann, Chief Financial Officer of Sartorius.
In view of high demand, the targeted minimum volume of 300 million euros was significantly exceeded. Most of the funds will be used for early repayment of the bridge loan that Sartorius had taken out at the end of April in connection with the acquisition of selected life science businesses from Danaher.
La mejor actitud que podemos adoptar es la de trat...
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
En nuestro post hablamos sobre este interesante tipo de célula del...
The results show that adenocarcinoma exhibits much more active and fun...
